Executive

TEAM

Paradigm’s leadership team is highly experienced in scientific discovery, regulatory affairs, drug development, clinical trials, finance, investor relations as well as licensing and commercialisation.

They are genuinely ‘experts in uncovering the real value of a molecule’.

Sharing a belief in repurposing and the potential it has to open up new treatment options for people around the globe, the team’s strategic plan centres upon ensuring Paradigm grows and fosters the knowledge, talent, experience and creativity necessary for long term success.

They lead by example in shaping a company culture that supports Paradigm’s Purpose and Vision.

Marco Polizzi
Chief Executive Officer

Mr. Polizzi has over 30 years of experience in the pharmaceutical industry in various commercially-focused roles, including the creation of new divisions within branded and generic pharmaceutical businesses. He has achieved outstanding sales results, forged a multitude of license, asset purchase, and other agreements with numerous top 10 global pharmaceutical companies, and generated significant returns for investors.

Mr. Polizzi’s proven track record is highlighted by a number of successful business and product launches in the USA. These include a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, driving the growth of a $900M P&L, as well as directing  commercial functions for a product launch (Bivalirudin) that achieved $100M+ sales in its first year.

Marco Polizzi
Chief Executive Officer

Mr. Polizzi has over 30 years of experience in the pharmaceutical industry in various commercially-focused roles, including the creation of new divisions within branded and generic pharmaceutical businesses. He has achieved outstanding sales results, forged a multitude of license, asset purchase, and other agreements with numerous top 10 global pharmaceutical companies, and generated significant returns for investors.

Mr. Polizzi’s proven track record is highlighted by a number of successful business and product launches in the USA. These include a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, driving the growth of a $900M P&L, as well as directing  commercial functions for a product launch (Bivalirudin) that achieved $100M+ sales in its first year.

Dr Donna Skerrett
Chief Medical Officer

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine,
cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a
stem cell development company, from 2011-19; Dir. Transfusion Medicine &
Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass.
Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital.
She has chaired the NY State Governor’s Council on Blood and Transfusion
Service and served on the Board of Directors of the Fox Chase Cancer Center.
She currently serves in an advisory role on the Board of Visitors for the Lewis
Katz School of Medicine of Temple University.

Dr Donna Skerrett
Chief Medical Officer

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company, from 2011-19; Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.

Justin Cahill
Chief Financial Officer

Mr Cahill has over 20 years’ experience in strategic finance roles across a
broad spectrum of industries and global organisations. In one of his more
recent and prominent roles, Justin spent 9 years at CSL, including 5 years as
Divisional CFO of CSL Plasma. Justin is a CPA and holds a Master’s in
Accounting. Experienced in global operations expansion, Mr Cahill oversees
the financial management of Paradigm’s growing portfolio and increasingly
complex activities.

Justin Cahill
Chief Financial Officer

Mr Cahill has over 20 years’ experience in strategic finance roles across a broad spectrum of industries and global organisations. In one of his more recent and prominent roles, Justin spent 9 years at CSL, including 5 years as Divisional CFO of CSL Plasma. Justin is a CPA and holds a Master’s in Accounting. Experienced in global operations expansion, Mr Cahill oversees the financial management of Paradigm’s growing portfolio and increasingly complex activities.

Dr Ravi Krishnan
Chief Scientific Officer

Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell
therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic
properties.

Dr Ravi Krishnan
Chief Scientific Officer

Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.

Simon White
Director of Investor Relations

Mr White brings a unique set of skills to his role. His career to date combines
experience in equity capital markets and the financial services sector (gained
as Corporate Advisory at DELCOR, a Melbourne based Family Office, and
Institutional Sales at Sequoia Wealth Management) with time as a high-
performance athlete (he was a professional footballer for the AFL team,
Carlton, for 8 years). His team-orientated approach and networking skills are
highly valued.

Simon White
Director of Investor Relations

Mr White brings a unique set of skills to his role. His career to date combines experience in equity capital markets and the financial services sector (gained as Corporate Advisory at DELCOR, a Melbourne based Family Office, and Institutional Sales at Sequoia Wealth Management) with time as a high- performance athlete (he was a professional footballer for the AFL team, Carlton, for 8 years). His team-orientated approach and networking skills are highly valued.

Cancel